CASIA OpenIR  > 脑网络组研究中心
Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis
Wuxiang Xie1; Fanfan Zheng2; Xiaoyu Song3; Baoliang Zhong4; Li Yan5
2016
发表期刊International Journal of Cardiology
期号205页码:65-71
摘要

BACKGROUND:

Renin-angiotensin-aldosterone system (RAAS) blockers are effective therapies for heart failure and reduced ejection fraction (HFrEF) or left ventricular dysfunction (LVD). We aimed to assess the efficacy and safety of RAAS blockers in these patients.

METHODS:

We searched MEDLINE, EMBASE, and Cochrane Library in May 2015. Twenty-one double-blind randomized controlled trials (RCTs) with 69,229 patients were included this network meta-analysis.

RESULTS:

Compared with placebo, an angiotensin receptor-neprilysin inhibitor (ARNI) had the highest probability of reducing all-cause mortality (odds ratio [OR]=0.67, 95% credible interval [CrI]: 0.48-0.86), followed by an aldosterone receptor antagonist (ARA, OR=0.74, 95% CrI: 0.62-0.88) and an angiotensin-converting enzyme inhibitor (ACEI, OR=0.80, 95% CrI: 0.71-0.89). The most efficacious therapy for preventing heart failure hospitalization was ARNI (OR=0.55, 95% CrI: 0.40-0.71), followed by combination therapy with an angiotensin II receptor blocker (ARB) plus an ACEI (OR=0.61, 95% CrI: 0.49-0.75), then an ACEI alone (OR=0.69, 95% CrI: 0.61-0.77). Sensitivity analysis restricted to nine RCTs with a high background use of ACEI and/or ARB (>80%) indicated that adding an ARA to current standard therapy significantly reduced mortality (OR=0.73, 95% CrI: 0.51-0.95) and hospitalization risk (OR=0.67, 95% CrI: 0.47-0.87), but did not significantly increase the discontinuation risk (OR=1.29, 95% CrI: 0.83-2.31).

CONCLUSIONS:

ARNI has the highest probability of being the most efficacious therapy for HFrEF in reducing death and hospitalization for heart failure. ARA has the most favorable benefit-risk profile as an adjunct to background ACEI and/or ARB therapy.

其他摘要英文摘要
关键词Heart Failure And Reduced Ejection Fraction Left Ventricular Dysfunction Renin–angiotensin–aldosterone System
文献类型期刊论文
条目标识符http://ir.ia.ac.cn/handle/173211/12121
专题脑网络组研究中心
通讯作者Wuxiang Xie
作者单位1.Department of Epidemiology, Beijing Anzhen Hospital
2.Brainnetome Center, Institute of Automation, Chinese Academy of Sciences
3.Department of Biostatistics, Columbia University
4.Department of Psychiatry, University of Rochester Medical Center
5.Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London
推荐引用方式
GB/T 7714
Wuxiang Xie,Fanfan Zheng,Xiaoyu Song,et al. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis[J]. International Journal of Cardiology,2016(205):65-71.
APA Wuxiang Xie,Fanfan Zheng,Xiaoyu Song,Baoliang Zhong,&Li Yan.(2016).Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.International Journal of Cardiology(205),65-71.
MLA Wuxiang Xie,et al."Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis".International Journal of Cardiology .205(2016):65-71.
条目包含的文件 下载所有文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
IJC-2016.pdf(603KB)期刊论文作者接受稿开放获取CC BY-NC-SA浏览 下载
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wuxiang Xie]的文章
[Fanfan Zheng]的文章
[Xiaoyu Song]的文章
百度学术
百度学术中相似的文章
[Wuxiang Xie]的文章
[Fanfan Zheng]的文章
[Xiaoyu Song]的文章
必应学术
必应学术中相似的文章
[Wuxiang Xie]的文章
[Fanfan Zheng]的文章
[Xiaoyu Song]的文章
相关权益政策
暂无数据
收藏/分享
文件名: IJC-2016.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。